Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Complementary Biomolecular Analysis Instruments Available for Research and Clinical Labs

By BiotechDaily International staff writers
Posted on 31 Mar 2014
Image: b-screen is a versatile biomolecular interaction analysis tool for biomolecular arrays in standard microscope format (Photo courtesy of Biametrics GmbH).
Image: b-screen is a versatile biomolecular interaction analysis tool for biomolecular arrays in standard microscope format (Photo courtesy of Biametrics GmbH).
Two new instruments for biomolecular analysis feature coated sensor chips (microarray format and mini format respectively) and assay protocols ready to support almost any research and development application from kinetic evaluation of microarrays to online immobilization.

The instruments—b-screen and b-portable—are products of Biametrics GmbH (Tübingen, Germany). Biametrics develops and markets label-free analytical system solutions for life science applications.

Biametrics has recently launched two new product lines intended to facilitate research in diverse types of life science laboratories. The b-screen device is able to handle any standard microarray format and can detect up to 10,000 bimolecular interactions in a single measurement. The b-portable device enables high quality label-free interaction analysis under laboratory or field conditions using a smart and inexpensive technology platform.

Current applications for b-screen include bioanalytics, drug discovery, production, and quality control. Based on the same technology, b-portable is a point-of-care device for early cancer and infection detection.

The b-screen instrument provides label-free read-out of up to 10,000 spots per square centimeter. It utilizes a precise and automated microfluidics system for incubation of the microarray with the sample of interest. The instrument can be used with multiple array layouts, uses glass or plastic type substrates, and is compatible with almost any common microarray printer. No fluorescence labels are needed, which leads to assay conditions similar to the in -vivo situation combined with minimal sample pretreatment and minimized reagent consumption.

Both b-screen and b-portable may be used with different sample types such as serum or whole blood or other relevant complex matrices such as cell culture medium. Kinetic data can be obtained for almost any kind of biomolecular interaction such as those between proteins, between peptides and proteins, and between small molecules and proteins.

“With b-screen users are able to easily transfer existing microarrays directly into a label-free assay format thus gaining additional information on kinetics and thermodynamics at high precision and reliability,” said Günther Proll, managing director of Biametrics. “The device allows very low cost high-throughput screening and the applications we have established demonstrate excellent performance and outcome characteristics. We believe b-screen provides key advantages over current options like surface plasmon resonance (SPR).”

Related Links:

Biametrics GmbH



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.